News
-
-
PRESS RELEASE
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC. The study shows favorable safety and injection feasibility, with promising survival data -
PRESS RELEASE
EQS-Adhoc: Basler AG: Basler publishes audited financial statements for the 2024 financial year, including a forecast for 2025 and a medium-term outlook
Basler AG publishes audited financial statements for 2024 with a forecast for 2025 and a medium-term outlook, revealing sales of Euro 183.7 million and EBITDA of Euro 10.0 million -
-
PRESS RELEASE
EQS-Adhoc: MBB SE proposes 15th consecutive base dividend increase to €1.11 and anniversary dividend of €2.22
MBB SE proposes 15th consecutive base dividend increase to €1.11 and anniversary dividend of €2.22. Total dividend of €3.33 per share. Annual Report 2024 to be published on 31 March 2025 -
PRESS RELEASE
Amaze Partners with Empact to Unlock $707.9B EU E-Commerce Market for Creators, Eliminating Surprise Fees and Expanding Global Reach
Amaze partners with Empact to enhance creator-fan shopping experience in EU. Collaboration tackles high shipping costs and delivers transparent pricing, faster delivery, and VAT compliance -
-
-
-
